11:40 AM EDT, 10/31/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target price to $100 from $93, 35x our 2026 EPS and a slight premium to the company's long-term average forward P/E. We lift our 2025 EPS to $2.58 from $2.49 and our 2026 EPS to $2.85 from $2.76. Our revised target price and estimates reflect strong Q3 results, with TAVR growth up a solid 10.6% in constant currency (Street was forecasting mid-single-digit growth), leading management to raise its full-year TAVR sales guide to 7%-8% from 6%-7%. All focus is now on 2026 and whether EW can deliver around 10% revenue growth, especially as comps get tougher. We're modeling 10% revenue growth in 2026, with EPS also growing 10% to $2.85 on the back of operating margin expansion and share buybacks. We expect FDA approval for Sapien M3 in the first half of 2026, though the launch will likely be gradual. We maintain our Buy opinion, viewing EW as one of the strongest earnings compounders among peers.